Full metadata record
DC Field | Value | Language |
---|---|---|
dc.creator | Herbst, R.S. (Roy S.) | - |
dc.creator | Baas, P. (P.) | - |
dc.creator | Perez-Gracia, J.L. (Jose Luis) | - |
dc.creator | Felip, E. (Enriqueta) | - |
dc.creator | Kim, D.W, (D. W.) | - |
dc.creator | Han, J.Y. (J. Y.) | - |
dc.creator | Molina, J.R. (J. R.) | - |
dc.creator | Kim, J.H. (J. H.) | - |
dc.creator | Dubos-Arvis, C. (C.) | - |
dc.creator | Ahn, M.J. (M. J.) | - |
dc.creator | Majem-Tarruella, M. (Margarita) | - |
dc.creator | Fidler, M.J. (M. J.) | - |
dc.creator | Surmont, V. (V.) | - |
dc.creator | Castro-Jr, G. (G.) de | - |
dc.creator | Garrido, M. (M.) | - |
dc.creator | Shentu, Y. (Y.) | - |
dc.creator | Emancipator, K. (K.) | - |
dc.creator | Samkari, A. (A.) | - |
dc.creator | Jensen, E.H. (E. H.) | - |
dc.creator | Lubiniecki, G.M (G. M.) | - |
dc.creator | Garon, E.B. (E. B.) | - |
dc.date.accessioned | 2021-09-20T09:20:52Z | - |
dc.date.available | 2021-09-20T09:20:52Z | - |
dc.date.issued | 2019 | - |
dc.identifier.citation | Herbst, R.S. (Roy S.); Baas, P. (P.); Perez-Gracia, J.L. (Jose Luis); et al. "Use of archival versus newly collected tumor samples for assessing PD-L1 expression and overall survival: an updated analysis of KEYNOTE-010 trial". Annals of Oncology. 30, 2019, 281 - 289 | es |
dc.identifier.issn | 0923-7534 | - |
dc.identifier.other | PMID: 30657853 | - |
dc.identifier.uri | https://hdl.handle.net/10171/62022 | - |
dc.description.abstract | Background: In KEYNOTE-010, pembrolizumab versus docetaxel improved overall survival (OS) in patients with programmed death-1 protein (PD)-L1-positive advanced non-small-cell lung cancer (NSCLC). A prespecified exploratory analysis compared outcomes in patients based on PD-L1 expression in archival versus newly collected tumor samples using recently updated survival data. Patients and methods: PD-L1 was assessed centrally by immunohistochemistry (22C3 antibody) in archival or newly collected tumor samples. Patients received pembrolizumab 2 or 10 mg/kg Q3W or docetaxel 75 mg/m2 Q3W for 24 months or until progression/intolerable toxicity/other reason. Response was assessed by RECIST v1.1 every 9 weeks, survival every 2 months. Primary end points were OS and progression-free survival (PFS) in tumor proportion score (TPS) ≥50% and ≥1%; pembrolizumab doses were pooled in this analysis. Results: At date cut-off of 24 March 2017, median follow-up was 31 months (range 23-41) representing 18 additional months of follow-up from the primary analysis. Pembrolizumab versus docetaxel continued to improve OS in patients with previously treated, PD-L1-expressing advanced NSCLC; hazard ratio (HR) was 0.66 [95% confidence interval (CI): 0.57, 0.77]. Of 1033 patients analyzed, 455(44%) were enrolled based on archival samples and 578 (56%) on newly collected tumor samples. Approximately 40% of archival samples and 45% of newly collected tumor samples were PD-L1 TPS ≥50%. For TPS ≥50%, the OS HRs were 0.64 (95% CI: 0.45, 0.91) and 0.40 (95% CI: 0.28, 0.56) for archival and newly collected samples, respectively. In patients with TPS ≥1%, OS HRs were 0.74 (95% CI: 0.59, 0.93) and 0.59 (95% CI: 0.48, 0.73) for archival and newly collected samples, respectively. In TPS ≥50%, PFS HRs were similar across archival [0.63 (95% CI: 0.45, 0.89)] and newly collected samples [0.53 (95% CI: 0.38, 0.72)]. In patients with TPS ≥1%, PFS HRs were similar across archival [0.82 (95% CI: 0.66, 1.02)] and newly collected samples [0.83 (95% CI: 0.68, 1.02)]. Conclusion: Pembrolizumab continued to improve OS over docetaxel in intention to treat population and in subsets of patients with newly collected and archival samples. | es_ES |
dc.description.sponsorship | This work was supported by Merck Sharp & Dohme Corp., a subsidiary of Merck & Co. Inc., Kenilworth, NJ, USA. No grant number is applicable for this funding source. This work was also supported by Yale SPORE in Lung Cancer (grant number P50CA196530-03). | es_ES |
dc.language.iso | eng | es_ES |
dc.publisher | Elsevier BV | es_ES |
dc.rights | info:eu-repo/semantics/openAccess | es_ES |
dc.subject | Materias Investigacion::Ciencias de la Salud::Oncología | es_ES |
dc.subject | PD-L1 expression | es_ES |
dc.subject | Pembrolizumab | es_ES |
dc.subject | Tumor samples | es_ES |
dc.title | Use of archival versus newly collected tumor samples for assessing PD-L1 expression and overall survival: an updated analysis of KEYNOTE-010 trial | es_ES |
dc.type | info:eu-repo/semantics/article | es_ES |
dc.description.note | cc-by-nc-nd | es_ES |
dc.identifier.doi | 10.1093/annonc/mdy545 | - |
dadun.citation.endingPage | 289 | es_ES |
dadun.citation.publicationName | Annals of Oncology | es_ES |
dadun.citation.startingPage | 281 | es_ES |
dadun.citation.volume | 30 | es_ES |
Files in This Item:
Statistics and impact
Items in Dadun are protected by copyright, with all rights reserved, unless otherwise indicated.